Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04149691
Other study ID # 01FGFR2018
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 19, 2019
Est. completion date June 2024

Study information

Verified date February 2024
Source Celon Pharma SA
Contact CROS CRO
Phone +48 791 690 990
Email clinicaltrials@cros-cro.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.


Description:

01FGFR2018 is an Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects with Advanced Solid Malignancies. The study consists of 3 parts: initial dose escalation (Part 1 - without FGFR, fibroblast growth factor receptor, molecular aberrations), dose escalation (Part 2 - with FGFR molecular aberrations) and dose extension (Part 3 - with FGFR molecular aberrations).


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria: - Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related - age of =25 years old - Performance Score =70 in accordance with the Karnofsky Performance Score (KPS), - life expectancy period of at least 3 months on the screening day, - Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception - adequate blood, liver, renal and urine parameters - phosphate levels within normal range - HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus), - adequate cardiac function Inclusion Criteria Specific for parts: Part 1 - Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options. Part 2 and 3 - Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options. - Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy. - Present molecular alteration within FGFR 1, 2 or 3 Exclusion Criteria: - Any other current malignancy or malignancy diagnosed within the past five (5) years. - Active brain metastases or leptomeningeal metastases. - concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment, - prior therapy with an agent directed to another FGFR inhibitor, - pregnancy and/or breastfeeding, - phosphate levels above the upper limit of normal, - ectopic calcification/mineralization, - endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy, - concomitant therapies increasing calcium/phosphate serum levels, - inability to take oral medicines, - corneal disorder and/or keratopathy, - persisting toxicity related to prior therapy Grade > 1 CTCAE v5.0, except polyneuropathy and alopecia, - clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment. - Receipt of any organ transplantation including allogeneic stem-cell transplantation. Exclusion Criteria Specific for parts: Part 2 and 3 - No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option.

Study Design


Intervention

Drug:
CPL304110
CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.

Locations

Country Name City State
Poland Uniwersyteckie Centrum Kliniczne w Gdansku Gdansk
Poland BioResearch Group sp. z o.o. Nadarzyn
Poland SP ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Olsztyn
Poland Klinika Onkologii, Europejskie Centrum Zdrowia Otwock
Poland Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Warsaw
Poland Instytut Gruzlicy i Chorób Pluc Warsaw
Poland Wojskowy Instytut Medyczny Warsaw

Sponsors (2)

Lead Sponsor Collaborator
Celon Pharma SA National Center for Research and Development, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) Maximum tolerated dose (MTD) of CPL304110 when administered orally once daily to adults with advanced solid malignancies. The MTD is the highest dose associated with the occurrence of dose-limiting toxicities (DLTs) in <33% of patients. First cycle of 28 days
Primary Safety profile Overall safety profile of CPL304110, as assessed by the type, frequency, severity, timing, and relationship to study drug of any adverse events (AEs), serious adverse events (SAEs), and changes in vital signs, ECGs, and safety laboratory test. First cycle of 28 days
Secondary Recommended Phase 2 Dose (RP2D) determined on the base of the MTD. The RP2D will be determined after review and discussion of the pharmacokinetics (PK) profile, type and severity of drug related toxicity and clinical suitability for long-term administration. Approximately up to 12 months
Secondary ORR, objective rate response ORR, objective rate response defined as the rate of confirmed complete response (CR) or partial response (PR) by RECIST 1.1. Approximately up to 12 months
Secondary Maximum plasma concentration (Cmax) Cmax defines the maximum concentration of the product in plasma during observation period. up to 24 hours after CPL304110 administration
Secondary Time to maximum plasma concentration (tmax) tmax defines Time to reach maximum plasma concentration up to 24 hours after CPL304110 administration
Secondary Area under the plasma concentration versus time curve (AUC) from 0 up to the time of last quantifiable concentration (AUC0-t) AUC(0-t) defines the area under the curve of plasma concentration vs time, from time point zero up to the time of last quantifiable concentration up to the time of last quantifiable concentration after CPL304110 administration
Secondary Area under the plasma concentration versus time curve AUC from 0 to infinity (AUC0-inf) AUC0-inf defines the area under the curve of plasma concentration vs time, from time point zero extrapolated to infinity up to 24 hours after CPL304110 administration
Secondary Terminal half-life (t½) Plasma elimination half-life up to 24 hours after CPL304110 administration
Secondary Kel: Terminal elimination rate constant Terminal elimination rate constant up to 24 hours after CPL304110 administration
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2